{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:00:15Z","timestamp":1790895615682,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s13318-017-0459-1","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T08:15:11Z","timestamp":1517818511000},"page":"431-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets"],"prefix":"10.1007","volume":"43","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7148-7926","authenticated-orcid":false,"given":"Bikui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"key":"459_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00004850-199503000-00003","volume":"10","author":"H He","year":"1995","unstructured":"He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995;10:19\u201330.","journal-title":"Int Clin Psychopharmacol"},{"key":"459_CR2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3565(25)13416-2","volume":"247","author":"JE Leysen","year":"1998","unstructured":"Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1998;247:661\u201370.","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 3","key":"459_CR3","first-page":"S89","volume":"38","author":"G Chouinard","year":"1993","unstructured":"Chouinard G, Arnott W. Clinical review of risperidone. Can J Psychiatr. 1993;38(Suppl 3):S89\u201395.","journal-title":"Can J Psychiatr"},{"issue":"6","key":"459_CR4","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","volume":"21","author":"G Mannens","year":"1993","unstructured":"Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos. 1993;21(6):1134\u201341.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"459_CR5","first-page":"6","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharm J. 2005;5(1):6\u201313.","journal-title":"Pharm J"},{"issue":"Suppl","key":"459_CR6","first-page":"13","volume":"55","author":"J Heykants","year":"1994","unstructured":"Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatr. 1994;55(Suppl):13\u20137.","journal-title":"J Clin Psychiatr"},{"key":"459_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/clpt.1993.146","volume":"54","author":"ML Huang","year":"1993","unstructured":"Huang ML, van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257\u201368.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 3","key":"459_CR8","first-page":"S80","volume":"38","author":"L Ereshefsky","year":"1993","unstructured":"Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatr. 1993;38(Suppl 3):S80\u20138.","journal-title":"Can J Psychiatr"},{"issue":"6","key":"459_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF02969428","volume":"29","author":"Hea-Young Cho","year":"2006","unstructured":"Cho Hea-Young, Lee Young-Bok. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch Pharm Res. 2006;29(6):525\u201333.","journal-title":"Arch Pharm Res"},{"issue":"5","key":"459_CR10","first-page":"452","volume":"13","author":"N Gonz\u00e1lez-Vacarezza","year":"2013","unstructured":"Gonz\u00e1lez-Vacarezza N, Abad-Santos F, Carcas-Sansuan A, Dorado P, Pe\u00f1as-Lled\u00f3 E, Est\u00e9vez Carrizo F, Llerena A. Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6. Pharm J. 2013;13(5):452\u20135.","journal-title":"Pharm J"},{"issue":"2","key":"459_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/bcpt.12286","volume":"116","author":"T Cabaleiro","year":"2015","unstructured":"Cabaleiro T, Ochoa D, Rom\u00e1n M, Moreno I, L\u00f3pez-Rodr\u00edguez R, Novalbos J, Abad-Santos F. Polymorphisms in CYP2D6 have a greater effect on variability of risperidone pharmacokinetics than gender. Basic Clin Pharmacol Toxicol. 2015;116(2):124\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"459_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s002280050615","volume":"55","author":"WJ Tamminga","year":"1999","unstructured":"Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, de Zeeuw RA, Jonkman JH. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999;55(3):177\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"459_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2125.2001.01328.x","volume":"51","author":"S Hagg","year":"2001","unstructured":"Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001;51(2):169\u201373.","journal-title":"Br J Clin Pharmacol"},{"key":"459_CR14","unstructured":"U.S. Department of Health and Human Services, FDA. Guidance for Industry-Bioanalytical method validation. U.S. Department of Health and Human Services, FDA, CDER. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm070107.pdf . Accessed 28 Apr 2015."},{"issue":"6","key":"459_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0149-2918(03)80163-7","volume":"25","author":"EA Schaick van","year":"2003","unstructured":"van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003;25(6):1687\u201399.","journal-title":"Clin Ther"},{"key":"459_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF02246543","volume":"122","author":"E Snoeck","year":"1995","unstructured":"Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R, Meibach R, Heykants J. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology. 1995;122:223\u20139.","journal-title":"Psychopharmacology"},{"issue":"6","key":"459_CR17","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.clinthera.2012.04.027","volume":"34","author":"Mingzhu Huang","year":"2012","unstructured":"Huang Mingzhu, Shen-Tu Jianzhong, Xingjiang Hu, Chen Junchun, Liu Jian, Lihua Wu. Comparative fasting bioavailability of dispersible and conventional tablets of Risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male Chinese volunteers. Clin Ther. 2012;34(6):1432\u20139.","journal-title":"Clin Ther"},{"issue":"1","key":"459_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40268-012-0002-4","volume":"13","author":"Yun Liu","year":"2013","unstructured":"Liu Yun, Zhang Meng-qi, Jia Jing-ying, Liu Yan-mei, Liu Gang-yi, Li Shui-jun, Wang Wei, Weng Li-ping, Chen Yu. Bioequivalence and pharmacokinetic evaluation of two formulations of risperidone 2\u00a0mg. Drugs R D. 2013;13(1):29\u201336.","journal-title":"Drugs R D"},{"issue":"2","key":"459_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0920-9964(99)00053-5","volume":"40","author":"DL Kelly","year":"1999","unstructured":"Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res. 1999;40(2):101\u20134.","journal-title":"Schizophr Res"},{"issue":"4","key":"459_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/0269881105053306","volume":"19","author":"W Aichhorn","year":"2005","unstructured":"Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig Schoeler R, Stuppaeck C, Geretsegger C. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005;19(4):395\u2013401.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"459_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/hup.2420","volume":"29","author":"T Cabaleiro","year":"2014","unstructured":"Cabaleiro T, Ochoa D, Lopez-Rodriguez R, Rom\u00e1n M, Novalbos J, Ayuso C, Abad-Santos F. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum Psychopharmacol Clin Exp. 2014;29(5):459\u201369.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"2","key":"459_CR22","first-page":"197","volume":"13","author":"B Almoguera","year":"2013","unstructured":"Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero Lorenzo C, Fernandez-Piqueras J, Llerena A, Abad-Santos F, Baca-Garc\u00eda E, Dal-R\u00e9 R, Ayuso C. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Pharm J. 2013;13(2):197\u2013204.","journal-title":"Pharm J"},{"issue":"10","key":"459_CR23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2217\/pgs.13.106","volume":"14","author":"R L\u00f3pez-Rodr\u00edguez","year":"2013","unstructured":"L\u00f3pez-Rodr\u00edguez R, Cabaleiro T, Ochoa D, Rom\u00e1n M, Borobia AM, Carcas AJ, Ayuso C, Novalbos J, Abad-Santos F. Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics. 2013;14(10):1203\u201311.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"459_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/FTD.0b013e3181c49a4c","volume":"32","author":"J Yong Chung","year":"2010","unstructured":"Yong Chung J, Jung Lee Y, Bok Jang S, Ahyoung Lim L, Soo Park M, Hwan Kim K. CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther Drug Monit. 2010;32(1):67\u201372.","journal-title":"Ther Drug Monit"},{"key":"459_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jpba.2016.05.013","volume":"128","author":"Xiaobing Li","year":"2016","unstructured":"Li Xiaobing, Shi Fuguo, He Xiaojing, Jian Lingyan, Ding Li. A rapid and sensitive LC-MS\/MS method for determination of lercanidipine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers. J Pharm Biomed Anal. 2016;128:67\u201372.","journal-title":"J Pharm Biomed Anal"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-017-0459-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T16:47:31Z","timestamp":1751302051000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-017-0459-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1007\/s13318-017-0459-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"5 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported in part by the Nature Science Foundation of China (No. 81401113), the Specialized Research Fund for the Doctoral Program of Higher Education of China (No. 20130162120060), and Hunan Provincial Natural Science Foundation of China (No. 2017JJ3444).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflict of interest in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in line with GCP, the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the School of Pharmaceutical Sciences, Central South University.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was signed by all volunteers before the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}